Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH925 in KRAS G12C-mutated Advanced Solid Tumors and NSCLC
CTR20211933Phase 2Completed
- Sponsor
- Zhejiang Jingfang Pharmaceutical
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulzerasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by Zhejiang Jingfang Pharmaceutical. Started Aug 2021; status: completed.
02
Drugs
fulzerasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211933.